Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
3.700
-2.080 (-35.99%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Today 11:32 EST
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Today 7:05 EST
Via
Benzinga
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
November 07, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
October 28, 2024
Via
Benzinga
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
August 12, 2024
Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.
Via
Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 28, 2024
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARC, K, RVNC on Behalf of Shareholders
October 18, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders
October 17, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 17, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 15, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 15, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
September 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
August 15, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
August 13, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Gold Gains Over 1%; Starbucks Shares Move Higher
August 12, 2024
Via
Benzinga
Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
August 12, 2024
Revance Therapeutics stock is up on Monday as RVNC investors celebrate a $924 million merger agreement with Crown Laboratories.
Via
InvestorPlace
Crude Oil Surges 2%; B. Riley Financial Shares Plunge
August 12, 2024
Via
Benzinga
Exposures
Fossil Fuels
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
August 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday
August 12, 2024
Via
Benzinga
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
Business Wire
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
August 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 08, 2024
RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
August 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
The big pharma company's top drug is losing ground, but its dividend keeps rising.
Via
The Motley Fool
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
July 11, 2024
Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside.
Via
InvestorPlace
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
May 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
May 22, 2024
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.